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Chronic treatment with clenbuterol, a âµ-adrenoceptor
agonist, has been proposed as a treatment to reverse the
muscle atrophy observed with ageing (Carter et al. 1991),
denervation (Maltin et al. 1987, 1993; Zeman et al. 1987;
Agbenyega & Wareham, 1990), muscle unloading (Delday &
Maltin, 1997) and muscle wasting diseases, such as muscular
dystrophy (Maltin et al. 1987, 1993; Martineau et al. 1992;
Zeman et al. 1994; Dupont-Versteegden, 1996). It is well
established that clenbuterol treatment increases muscle mass in
a number of different species (Kim & Sainz, 1992) with an
increased protein synthesis andÏor decreased protein
degradation proposed as the mechanism for the hypertrophy
of skeletal muscle (Choo et al. 1992; Moore et al. 1994).
As a strategy for treating muscular dystrophy, major
inconsistencies exist regarding the effect of clenbuterol on the
functional properties of skeletal muscles of dystrophic mdx
mice. Hayes & Williams (1994) and Dupont-Versteegden and
colleagues (1995) treated young (3-week-old) mdx mice with
clenbuterol for 3 and 15 weeks, respectively, and both groups
reported increases in absolute maximum isometric force (Pï)
for soleus muscles of treated mice relative to untreated mice.
Only Hayes & Williams (1994) reported a greater specific Pï
(force normalised to muscle cross-sectional area) for the soleus
muscles, although Pï was normalised only for muscle mass. In
another study, Zeman et al. (1994) reported that the Pï for
EDL muscles of clenbuterol-treated mice was 131% that for
untreated mdx mice. This finding is confounded by a value of
Pï that was only 40% of the values normally reported for
EDL muscles of mice (Brooks & Faulkner, 1988, 1991;
Dupont-Versteegden et al. 1995; Lynch et al. 1999).
A major function of skeletal muscle is the generation of power
output to do work and provide bodily motion (Wilkie, 1960).
Data exist on the absolute and normalised power outputs of
diaphragm muscles and also recently on limb muscles of mdx
mice (Lynch et al. 1997; Deconinck et al. 1998). No data are
available on the effect of clenbuterol treatment on power
output of limb muscles of mdx mice. After 52 weeks of
clenbuterol treatment of control mice, Lynch et al. (1999)
reported increased muscle masses for the EDL and soleus
muscles but no differences in absolute or normalised Pï or
power output of these muscles. Since previous studies have
only looked at the effect of clenbuterol on the isometric
contractile properties of dystrophic skeletal muscle, the
purpose of this study was to investigate the effects of 20 weeks
of clenbuterol treatment on the dynamic properties of skeletal
muscles from mdx and control mice. We tested the null
hypothesis that clenbuterol treatment (•2 mg kg¢ day¢)
would not affect absolute and normalised force and power
output of EDL and soleus muscles of mdx and control mice.
METHODS
Animal groups and drug administration
Six-month-old male specific pathogen-free (SPF) mdx and control
(C57BLÏ10ScSn mice) were obtained from Jackson Laboratories
(Bar Harbor, ME, USA) and housed at The University of Michigan
in barrier protected facilities and provided with standard laboratory
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chow and water ad libitum. All experiments on the mice were
conducted in accordance with the guidelines outlined in the Guide
for the Care and Use of Laboratory Animals (DHEW Publication
No. 85-23 (NIH) Revised 1985, Office of Science and Health
Reports, DRRÏNIH, Bethesda, MD 20205, USA). The mdx and
control mice were separated into either a treated or an untreated
group. The mice in the treated group were administered clenbuterol
(Sigma Chemical Company, 1.5 to 2 mg kg¢ day¢) in their drinking
water, every day for the first week. A ‘3 day on—3 day off’ cycle was
employed for weeks 2—20 in order to reduce attenuation of the
clenbuterol response (Yang & McElligott, 1989). The clenbuterol
solution was freshly prepared each week to avoid oxidation and
possible reduction in its efficacy. The effectiveness of clenbuterol
administration via the drinking water and the dosage are well-
established (Zeman et al. 1988; Hayes & Williams, 1994; Moore et
al. 1994; Dupont-Versteegden et al. 1995; Lynch et al. 1996). The
duration of the clenbuterol treatment was 20 weeks. A relatively
high dosage of clenbuterol was administered in order to determine
the maximum effects of the âµ-agonist on skeletal muscle.
Two days after the completion of the last treatment period, mice
were anaesthetised deeply with pentobarbital sodium (70 mg kg¢,
i.p.) such that no response occurred to tactile stimuli. The fast-twitch
extensor digitorum longus (EDL), and the predominantly slow-
twitch soleus muscles were surgically excised from the left hind-
limb. The deeply anaesthetised mice were killed by the creation of a
pneumothorax.
Contractile properties
Contractile properties of EDL and soleus muscles were measured in
vitro by techniques that we have described previously (Lynch et al.
1999). Briefly, silk suture was tied to each tendon of the isolated
muscles. The muscles were placed in an experimental chamber filled
with Ringer solution (containing (mÒ): NaCl 137; NaHCO× 24;
glucose 11; KCl 5; CaClµ 2; MgSOÚ 1; NaHµPOÚ 1; and tubo-
curarine chloride 0.025; pH 7.4) oxygenated with 95% Oµ and 5%
COµ and maintained at 25°C. Muscles were aligned horizontally
between a lever arm of a position feedback servomotor (model
300H, Cambridge Technology Inc. Watertown, MA, USA) and the
stainless steel hook of a force transducer (model BG-50, Kulite
Semiconductor Products Inc., Leonia, NJ, USA). The muscles were
stimulated directly by an electric field between two platinum plate
electrodes placed longitudinally on either side of the muscle. Square
wave pulses 0.2 ms in duration were produced by a stimulator
(model S88, Grass Instruments) and amplified (model DC-300A
Series II, Crown International Inc., Elkhart, IN, USA) to increase
and sustain current intensity to a sufficient level to produce a
maximum isometric tetanic contraction. Stimulation voltage and
muscle length (Lï) were adjusted to obtain maximum isometric
twitch force. Optimum fibre length (Lf) was determined by
multiplying Lï by fibre length to muscle length ratios determined
previously (Brooks & Faulkner, 1988; Lynch et al. 1999). The
ratios used were 0.44 for the EDL muscle and 0.71 for the soleus
muscle. Maximum isometric tetanic force production (Pï) was
determined from the plateau of the frequency—force relationship.
Power output was determined by isovelocity shortenings during
maximum muscle activation. Initiation of the isovelocity shortening
ramp and stimulation of the muscle occurred simultaneously.
Stimulation was terminated at the end of the shortening ramp and
the muscle was held isometric for 100 ms allowing it to relax before
returning to resting length (see Fig. 1). For the EDL and soleus
muscles, power output was determined initially from isovelocity
shortenings from 105% Lf to 95% Lf during maximum muscle
activation which allowed the muscle to shorten an equal distance
either side of Lï (Brooks et al. 1990). When a maximum power
measurement was determined, further isovelocity shortenings were
made from 100% Lf to 90% Lf. Frequently, a higher value for
maximum power output was achieved employing this protocol.
Maximum power output was determined from whichever of the two
protocols yielded the highest value and calculated as the product of
average force and velocity of shortening. The average force
generated during the shortening ramp was determined by integrating
the area under the force curve and dividing by the elapsed time. This
method gives slightly lower estimates of muscle power than that
obtained following analysis of force (P)—velocity (V) relationships
(Ranatunga, 1998). The velocity of shortening and the frequency of
stimulation were adjusted to elicit maximum power output. The
optimum shortening velocity (Vopt) was defined as the velocity at
which the power was maximum (Brooks et al. 1990). After the
contractile properties were measured, each muscle was trimmed of
its tendons and visible connective tissue, blotted on filter paper, and
weighed on an analytical balance (Mettler AE-50). The total muscle
fibre cross-sectional area (CSA) of the muscles was determined by
dividing muscle mass (mg) by the product of Lf and 1.06 mg mm¦Å,
the density of mammalian skeletal muscle (M endez & Keys, 1960).
The values for specific force (kN m¦Â) were normalised to CSA and
power (W) was normalised to muscle mass (W kg¢).
Statistical analysis
Results are presented in the tables as means ± s.e.m. Using NCSS
software (Number Cruncher Statistical System 5.01, Kaysville, UT,
USA), differences were assessed using a two-way analysis of
variance (ANOVA) for mouse strain (mdx vs. control) and
treatment (treated vs. untreated), with the Student-Newman-Keul’s
multiple comparison procedure used to identify specific differences
when significance was detected. Specific comparisons were made
between untreated mdx and untreated control mice, treated and
untreated control mice and treated and untreated mdx mice. The
level of significance was set a priori at P < 0.05.
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Figure 1
Experimental record of an isovelocity shortening contraction
used to calculate power during a single tetanic contraction of
an isolated EDL muscle (control, treated group). Upper trace
indicates displacement of muscle length by the lever arm of the
servomotor. Lower trace shows the corresponding force
generated by the muscle. Arrows indicate times at which
stimulation began and stopped. Power was calculated using the
ramp velocity and average force during the ramp as described
in the Methods.
RESULTS
Comparisons of data from untreated mdx and
untreated control mice
The body masses of the 11-month-old mdx and control mice
were not different (Table 1). As reported previously (Dupont-
Versteegden et al. 1995; Faulkner et al. 1997), compared
with the masses of the EDL and soleus muscles of control
mice, those of mdx mice were 130% and 140%, respectively.
Despite the hypertrophy of the muscles in the mdx compared
with the control mice, the absolute Pï and power of EDL
muscles of mdx mice were not different from those of control
mice (Table 2). In contrast, absolute Pï and power of the
soleus muscles of mdx mice were 121% and 124%,
respectively, of the values for control mice ( Table 2). For
specific Pï and the normalised power, values for EDL muscles
from mdx mice were 84% and 76%, respectively, of the
values for the control mice, whereas no differences were
observed for soleus muscles.
Effects of clenbuterol administration on body and
muscle masses
Following clenbuterol treatment, the body masses of mdx and
control mice were not different from the untreated mice in
their respective groups (Table 1). For control mice, the mass of
the EDL muscles of treated compared with untreated mice
was 109%, but the masses of soleus muscles in treated and
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Table 1. Selected morphological characteristics of adult control (C57BLÏ10) and mdx mice following




Untreated Treated Untreated Treated
(n = 11) (n = 11) (n = 11) (n = 11)
––––––––––––––––––––––––––––––––––––––––––––––
Body mass (g) 38 ± 1 33 ± 1 36 ± 1 37 ± 1
EDL muscle
Mass (mg) 12.6 ± 0.3 13.7 ± 0.4* 16.4 ± 0.4† 17.9 ± 0.6
CSA (mm
2
) 2.0 ± 0.1 2.2 ± 0.1* 2.5 ± 0.1 2.8 ± 0.1*
Lf (mm) 5.9 ± 0.1 5.9 ± 0.1 6.1 ± 0.1 6.1 ± 0.1
Soleus muscle
Mass (mg) 10.3 ± 0.4 10.7 ± 0.1 14.6 ± 0.5† 16.3 ± 0.4*
CSA (mm
2
) 1.2 ± 0.1 1.3 ± 0.1 1.6 ± 0.1 1.8 ± 0.1*
Lf (mm) 8.2 ± 0.2 7.8 ± 0.1 8.6 ± 0.1 8.6 ± 0.1
––––––––––––––––––––––––––––––––––––––––––––––
EDL, extensor digitorum longus; CSA, cross-sectional area; Lf, muscle fibre length. Values for muscle
massÏbody mass (relative mass) are expressed (mg g¢ ² 1000); * Significant differences (P < 0.05) between
untreated and treated mice of each group; † significant differences (P < 0.05) between control and mdx mice.
––––––––––––––––––––––––––––––––––––––––––––––
Table 2. Contractile properties of extensor digitorum longus (EDL) and soleus muscles from control




Untreated Treated Untreated Treated
(n = 11) (n = 11) (n = 11) (n = 11)
––––––––––––––––––––––––––––––––––––––––––––––
EDL muscles
Po (mN) 507 ± 13.1 518 ± 19.5 532 ± 14.5 557 ± 18.1
Po (kN m¦Â) 253 ± 6.5 236 ± 5.3 214 ± 6.7† 201 ± 6.0
Vopt (Lf s¢) 1.59 ± 0.04 1.60 ± 0.04 1.57 ± 0.04 1.67 ± 0.04
Power (mW) 1.59 ± 0.09 1.59 ± 0.08 1.58 ± 0.04 1.88 ± 0.09*
Power (W kg¢) 126 ± 5.6 116 ± 5.8 96 ± 4.2† 105 ± 4.5
Soleus muscles
Po (mN) 276 ± 5.6 298 ± 14.1 334 ± 12.8 347 ± 8.7
Po (kN m¦Â) 236 ± 9.1 230 ± 12.1 212 ± 12.6 195 ± 10.0
Vopt (Lf s¢) 0.67 ± 0.04 0.77 ± 0.05 0.52 ± 0.03† 0.59 ± 0.03
Power (mW) 0.33 ± 0.02 0.35 ± 0.03 0.41 ± 0.03† 0.50 ± 0.04
Power (W kg¢) 32 ± 1.7 33 ± 3.1 28 ± 2.2 31 ± 2.4
––––––––––––––––––––––––––––––––––––––––––––––
Po, tetanic force; Vopt, optimum velocity for maximum power output. * Significant differences (P < 0.05)
between untreated and treated mice of each group; † significant differences (P < 0.05) between control and
mdx mice.
––––––––––––––––––––––––––––––––––––––––––––––
untreated mice were not different. For treated compared with
untreated mdx mice, the mass of soleus muscles was 112%,
whereas the EDL muscle did not show any difference.
Effects of clenbuterol administration on contractile
properties
The EDL and soleus muscles of treated and untreated control
mice did not differ in any of the contractile measurements
(Table 2). For treated compared with untreated mdx mice, the
only difference in any of the contractile properties of EDL or
soleus muscles was the value of 118% for the absolute power
of the EDL muscle (Table 2). Thus, the null hypothesis that
clenbuterol administration would not affect the force and
power output of skeletal muscles from dystrophic mice was
supported, with the single exception of the normalised power
of the EDL muscle.
DISCUSSION
Although the potential therapeutic role for clenbuterol in
muscular dystrophy has received much attention (Maltin et al.
1987, 1993; Martineau et al. 1992; Zeman et al. 1994; Hayes
& Williams 1994; Dupont-Versteegden et al. 1995), the
majority of these studies have investigated only whether
clenbuterol alters the mass and isometric force-producing
capacity of isolated muscles. Whether clenbuterol affects the
dynamic properties of dystrophic skeletal muscle has not been
addressed. Since the ability of skeletal muscles to do work and
provide bodily motion is dependent upon the generation of
power output, the therapeutic potential of clenbuterol is tested
more rigorously by investigating its effects on the power
output of dystrophic skeletal muscles. In this study, we found
that clenbuterol treatment produced only modest changes in
the dynamic properties of fast- and slow-twitch skeletal
muscles of the mdx mouse.
The continuous cycle of degeneration and regeneration
associated with the dystrophic process in mdx mice appears to
initiate a hypertrophy that is sustained if not augmented
during the first 12 months of the life of the mouse (Faulkner et
al. 1997). This hypertrophy does much to maintain the absolute
force and power of the limb muscles of dystrophic mice close
to the values for control mice. For mice 6—12 months of age,
several different studies have reported the masses of small
limb muscles of untreated mdx mice to be 125—150% of the
values for control mice (for review see Faulkner et al. 1997).
Our values for EDL and soleus muscles of 11-month-old
untreated mdx mice compared with untreated control mice of
130% to 142% are in excellent agreement with the published
values. For limb muscles of both mdx mice and control mice
and rats, published data are contradictory regarding the effects
of clenbuterol on absolute muscle masses (Agbenyega &
Wareham, 1990; Hayes & Williams 1994; Dupont-
Versteegden et al. 1995; Dodd et al. 1996). Based on both the
published data and our data on the EDL and soleus muscles of
mdx and control mice, the effects of clenbuterol continue to be
unpredictable and inconclusive for both fast and slow skeletal
muscles. Clenbuterol treatment produced for both fast and slow
muscles either a modest •10% hypertrophy, or no change.
Following both short-term and long-term administration of
clenbuterol, a number of investigators have reported a greater
absolute Pï for EDL muscles of mdx mice (Zeman et al. 1994)
and soleus muscles of both mdx and control mice (Hayes &
Williams, 1994; Dupont-Versteegden et al. 1995). In the
present study, only the EDL muscles of the treated mdx mice
showed any difference, with absolute power increased to
118% that of the untreated mdx mice. The greater absolute
power of the treated compared with the untreated mdx mice
arose from small insignificant differences in both force and
Vopt. All the other muscles of clenbuterol-treated mdx or
control mice showed no difference in absolute force or power
or a small loss. Our data provide little support for clenbuterol
treatment producing any change in the development of
absolute force or power of skeletal muscles.
Some conflicting results have appeared (Hayes & Williams
1994), but most short- and long-term treatments of control
rats with clenbuterol have shown no difference in specific Pï of
limb muscles (Zeman et al. 1988; Dodd et al. 1996; Van der
Heijden et al. 1998; Lynch et al. 1999). Similarly, we found
no evidence to support any increase in specific force of fast or
slow limb muscles following clenbuterol treatment of either
mdx or control mice. As with the specific force, no differences
in normalised power were observed for either limb muscle of
treated or untreated mdx or control mice. We conclude that
clenbuterol was ineffective in improving the specific force or
normalised power output of dystrophic skeletal muscles.
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